Novel compounds and compositions as cathepsin inhibitors
申请人:Aventis Pharmaceuticals Inc.
公开号:US20040142999A1
公开(公告)日:2004-07-22
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS
申请人:AXYS PHARMACEUTICALS, INC.
公开号:EP1397340A2
公开(公告)日:2004-03-17
[EN] NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSES ET COMPOSITIONS UTILISES EN TANT QU'INHIBITEURS DE CATHEPSINE
申请人:AXYS PHARM INC
公开号:WO2002098850A2
公开(公告)日:2002-12-12
The present invention relates to coumponds of formula (I) (in which X1 is-NHC(R1)(R2)X3 or -NHX4 and the other variables are as defined in the claims) and the pharmaceutically acceptable salts and N-oxides therof, useful as selective cathepsin S inhibitors, their uses as therapeutic agents and the methods for their making. Formula (I):
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.